Where this storyline stands
The death of a six-year-old girl after receiving an experimental gene-editing therapy has been described by scientists as a tragedy that highlights the need to improve trial safeguards. But some in the biotechnology industry fear Chinese policymakers may curtail the regulatory flexibility that scientists have long enjoyed in initiating clinical trials – a key mechanism behind China’s competitive edge in frontier trea
Complete chronological journey
Every chapter below is ordered by its exact event time, from the earliest connected report to the newest development.
- 01How it started01 — How it started
Is China’s biotech boom at risk? Fear of policy backlash after death in gene-editing trial
What happened
The death of a six-year-old girl after receiving an experimental gene-editing therapy has been described by scientists as a tragedy that highlights the need to improve trial safeguards. But some in the biotechnology industry fear Chinese policymakers may curta Is China’s biotech boom at risk? Fear of policy backlash after death in gene-editing trial
Why it matters
The development may affect public safety, diplomacy, policy and people living in the region. Early claims can change quickly, so verified updates and clear attribution are essential.